scholarly journals Precautions for avoiding pulmonary morbidity after esophagectomy

2020 ◽  
Vol 4 (5) ◽  
pp. 480-484
Author(s):  
Naoya Yoshida ◽  
Kazuto Harada ◽  
Masaaki Iwatsuki ◽  
Yoshifumi Baba ◽  
Hideo Baba
Keyword(s):  
Pulmonary Morbidity

Cough Peak Flow as a Predictor of Pulmonary Morbidity in Patients with Dysphagia

2012 ◽  
Vol 91 (9) ◽  
pp. 783-788 ◽  
Author(s):  
Carlo Bianchi ◽  
Paola Baiardi ◽  
Sonia Khirani ◽  
Giovanna Cantarella
Keyword(s):  
Peak Flow ◽  
Pulmonary Morbidity

scholarly journals 200 Circulating Pro-Endothelin-1 (CT-proET-1) and Pulmonary Morbidity in Newborn Infants

2012 ◽  
Vol 97 (Suppl 2) ◽  
pp. A58-A58
Author(s):  
S. Wellmann ◽  
J. Benzing ◽  
O. Stabile ◽  
G. Szinnai ◽  
N. Morgenthaler ◽  
...  
Keyword(s):  
Newborn Infants ◽  
Endothelin 1 ◽  
Pulmonary Morbidity

scholarly journals P-181 * POSTOPERATIVE PULMONARY MORBIDITY IS NOT INFLUENCED BY THE SIZE OF THE THORACOTOMY IN PATIENTS WITH LOW PULMONARY VOLUMES

2014 ◽  
Vol 18 (suppl 1) ◽  
pp. S48-S48
Author(s):  
M. Rodriguez ◽  
M. T. Gomez-Hernandez ◽  
N. Novoa ◽  
J. L. Aranda ◽  
M. F. Jimenez ◽  
...  
Keyword(s):  
Pulmonary Volumes ◽  
Pulmonary Morbidity

scholarly journals Pulmonary Morbidity in Infancy after Exposure to Chorioamnionitis in Late Preterm Infants

2016 ◽  
Vol 13 (6) ◽  
pp. 867-876 ◽  
Author(s):  
Karen M. McDowell ◽  
Alan H. Jobe ◽  
Matthew Fenchel ◽  
William D. Hardie ◽  
Tate Gisslen ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Late Preterm ◽  
Late Preterm Infants ◽  
Pulmonary Morbidity

scholarly journals Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors

2018 ◽  
Vol 36 (29) ◽  
pp. 2950-2954 ◽  
Author(s):  
Adam C. Calaway ◽  
Richard S. Foster ◽  
Nabil Adra ◽  
Timothy A. Masterson ◽  
Costa Albany ◽  
...  
Keyword(s):  
Germ Cell ◽  
Operative Time ◽  
Germ Cell Tumors ◽  
Supplemental Oxygen ◽  
Retroperitoneal Lymph Node Dissection ◽  
Retroperitoneal Lymph Node ◽  
Operative Morbidity ◽  
Estimated Blood Loss ◽  
Good Risk ◽  
Pulmonary Morbidity

Purpose Three cycles of bleomycin, etoposide, and cisplatin (BEP × 3) or four cycles of etoposide and cisplatin (EP × 4) are first-line chemotherapy regimens for men with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk germ cell tumors (GCTs). We determined whether inclusion of bleomycin affected pulmonary and operative morbidity after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). Patients and Methods We queried our database to identify IGCCCG good-risk patients who received BEP × 3 or EP × 4 induction chemotherapy before PC-RPLND from 2006 to 2016. Patients who received combination regimens were excluded. The primary outcomes of interest were pulmonary morbidity (prolonged intubation, reintubation, supplemental oxygen use, intensive care unit stay) and operative morbidity (operative time, length of stay, concomitant procedures, estimated blood loss). Results We analyzed 234 patients (191 BEP × 3 v 43 EP × 4). All patients were extubated immediately after the operation. None were reintubated or discharged on oxygen. Two patients in each cohort required an intensive care unit stay for nonpulmonary reasons. Patients treated with BEP required shorter use of supplemental oxygen (0.99 v 1.63 days; P = .005). No significant differences were found in preoperative mass size ( P = .42) or concomitant surgeries ( P = .58). Operative time was significantly shorter (131 v 170 minutes; P < .01), and estimated blood loss was considerably less (194 v 226 mL; P < .01) in patients treated with BEP. Length of stay was shorter in patients treated with BEP (3.3 v 3.9 days; P < .01). Conclusion In a modern surgical cohort, the inclusion of bleomycin does not seem to influence pulmonary morbidity, operative difficulty, or nonpulmonary postoperative complications after PC-RPLND in men with IGCCCG good-risk GST.

Sign in / Sign up

Export Citation Format

Share Document